π¬ New antibody keeps inflammation low for six months
A monoclonal antibody designed to target interleukin-6 successfully achieved sustained reductions in inflammation biomarkers. This promising treatment was studied by researchers at Medical Xpress. The results showed positive effects maintained over a period of six months. This breakthrough offers new hope for managing chronic inflammatory conditions. Further clinical trials are planned to evaluate its long-term effectiveness. π¬